Subependymal giant cell astrocytoma epidemiology and demographics: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| (5 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Subependymal giant cell astrocytoma}} | {{Subependymal giant cell astrocytoma}} | ||
{{CMG}}{{AE}}{{SR}} | {{CMG}} {{AE}}{{IO}}, {{SR}} | ||
==Overview== | ==Overview== | ||
Subependymal giant cell astrocytoma is the most common central nervous system tumor in patients with tuberous sclerosis complex. Approximately 10-20% of patients with [[tuberous sclerosis]] develop subependymal giant cell astrocytoma. | Subependymal giant cell astrocytoma is the most common [[central nervous system]] [[tumor]] in patients with [[tuberous sclerosis complex]]. Approximately 10-20% of patients with [[tuberous sclerosis]] develop subependymal giant cell astrocytoma. It is a disease that tends to commonly affect the pediatric population with males being more affected than females. | ||
==Epidemiology and Demographics== | ==Epidemiology and Demographics== | ||
===Incidence=== | ===Incidence=== | ||
*The incidence of subependymal giant cell astrocytoma is approximately 0.027 per 100,000 person-years.<ref name="pmid29966782">{{cite journal| author=Nguyen HS, Doan NB, Gelsomino M, Shabani S, Awad AJ, Best B et al.| title=Subependymal Giant Cell Astrocytoma: A Surveillance, Epidemiology, and End Results Program-Based Analysis from 2004 to 2013. | journal=World Neurosurg | year= 2018 | volume= 118 | issue= | pages= e263-e268 | pmid=29966782 | doi=10.1016/j.wneu.2018.06.169 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=29966782 }} </ref> | *The [[incidence]] of subependymal giant cell astrocytoma is approximately 0.027 per 100,000 person-years.<ref name="pmid29966782">{{cite journal| author=Nguyen HS, Doan NB, Gelsomino M, Shabani S, Awad AJ, Best B et al.| title=Subependymal Giant Cell Astrocytoma: A Surveillance, Epidemiology, and End Results Program-Based Analysis from 2004 to 2013. | journal=World Neurosurg | year= 2018 | volume= 118 | issue= | pages= e263-e268 | pmid=29966782 | doi=10.1016/j.wneu.2018.06.169 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=29966782 }} </ref> | ||
===Prevalence=== | ===Prevalence=== | ||
*Subependymal giant cell astrocytoma is the most common central nervous system tumor in patients with tuberous sclerosis complex.<ref name="OuyangZhang2014">{{cite journal|last1=Ouyang|first1=Taohui|last2=Zhang|first2=Na|last3=Benjamin|first3=Thomas|last4=Wang|first4=Long|last5=Jiao|first5=Jiantong|last6=Zhao|first6=Yiqing|last7=Chen|first7=Jian|title=Subependymal giant cell astrocytoma: current concepts, management, and future directions|journal=Child's Nervous System|volume=30|issue=4|year=2014|pages=561–570|issn=0256-7040|doi=10.1007/s00381-014-2383-x}}</ref> | *Subependymal giant cell astrocytoma is the most common [[central nervous system]] [[tumor]] in patients with [[tuberous sclerosis complex]].<ref name="OuyangZhang2014">{{cite journal|last1=Ouyang|first1=Taohui|last2=Zhang|first2=Na|last3=Benjamin|first3=Thomas|last4=Wang|first4=Long|last5=Jiao|first5=Jiantong|last6=Zhao|first6=Yiqing|last7=Chen|first7=Jian|title=Subependymal giant cell astrocytoma: current concepts, management, and future directions|journal=Child's Nervous System|volume=30|issue=4|year=2014|pages=561–570|issn=0256-7040|doi=10.1007/s00381-014-2383-x}}</ref> | ||
*Approximately 10-20% of patients with [[tuberous sclerosis]] develop subependymal giant cell astrocytoma.<ref name="RothRoach2013">{{cite journal|last1=Roth|first1=Jonathan|last2=Roach|first2=E. Steve|last3=Bartels|first3=Ute|last4=Jóźwiak|first4=Sergiusz|last5=Koenig|first5=Mary Kay|last6=Weiner|first6=Howard L.|last7=Franz|first7=David N.|last8=Wang|first8=Henry Z.|title=Subependymal Giant Cell Astrocytoma: Diagnosis, Screening, and Treatment. Recommendations From the International Tuberous Sclerosis Complex Consensus Conference 2012|journal=Pediatric Neurology|volume=49|issue=6|year=2013|pages=439–444|issn=08878994|doi=10.1016/j.pediatrneurol.2013.08.017}}</ref> | *Approximately 10-20% of patients with [[tuberous sclerosis]] develop subependymal giant cell astrocytoma.<ref name="RothRoach2013">{{cite journal|last1=Roth|first1=Jonathan|last2=Roach|first2=E. Steve|last3=Bartels|first3=Ute|last4=Jóźwiak|first4=Sergiusz|last5=Koenig|first5=Mary Kay|last6=Weiner|first6=Howard L.|last7=Franz|first7=David N.|last8=Wang|first8=Henry Z.|title=Subependymal Giant Cell Astrocytoma: Diagnosis, Screening, and Treatment. Recommendations From the International Tuberous Sclerosis Complex Consensus Conference 2012|journal=Pediatric Neurology|volume=49|issue=6|year=2013|pages=439–444|issn=08878994|doi=10.1016/j.pediatrneurol.2013.08.017}}</ref> | ||
===Age=== | ===Age=== | ||
*Subependymal giant cell astrocytoma is a disease that tends to affect the pediatric, adolescent, and young adult population.<ref name="pmid21465222">{{cite journal| author=Campen CJ, Porter BE| title=Subependymal Giant Cell Astrocytoma (SEGA) Treatment Update. | journal=Curr Treat Options Neurol | year= 2011 | volume= 13 | issue= 4 | pages= 380-5 | pmid=21465222 | doi=10.1007/s11940-011-0123-z | pmc=PMC3130084 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21465222 }} | *Subependymal giant cell astrocytoma is a disease that tends to affect the pediatric, adolescent, and young adult population.<ref name="pmid21465222">{{cite journal| author=Campen CJ, Porter BE| title=Subependymal Giant Cell Astrocytoma (SEGA) Treatment Update. | journal=Curr Treat Options Neurol | year= 2011 | volume= 13 | issue= 4 | pages= 380-5 | pmid=21465222 | doi=10.1007/s11940-011-0123-z | pmc=PMC3130084 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21465222 }} </ref> | ||
*The mean age at diagnosis is 13 years.<ref name="NabboutSantos1999">{{cite journal|last1=Nabbout|first1=R|last2=Santos|first2=M|last3=Rolland|first3=Y|last4=Delalande|first4=O|last5=Dulac|first5=O|last6=Chiron|first6=C|title=Early diagnosis of subependymal giant cell astrocytoma in children with tuberous sclerosis|journal=Journal of Neurology, Neurosurgery & Psychiatry|volume=66|issue=3|year=1999|pages=370–375|issn=0022-3050|doi=10.1136/jnnp.66.3.370}}</ref> | *The mean age at [[diagnosis]] is 13 years.<ref name="NabboutSantos1999">{{cite journal|last1=Nabbout|first1=R|last2=Santos|first2=M|last3=Rolland|first3=Y|last4=Delalande|first4=O|last5=Dulac|first5=O|last6=Chiron|first6=C|title=Early diagnosis of subependymal giant cell astrocytoma in children with tuberous sclerosis|journal=Journal of Neurology, Neurosurgery & Psychiatry|volume=66|issue=3|year=1999|pages=370–375|issn=0022-3050|doi=10.1136/jnnp.66.3.370}}</ref> | ||
*It commonly presents in the first two decades of life.<ref name="pmid26942030">{{cite journal| author=Stein JR, Reidman DA| title=Imaging Manifestations of a Subependymal Giant Cell Astrocytoma in Tuberous Sclerosis. | journal=Case Rep Radiol | year= 2016 | volume= 2016 | issue= | pages= 3750450 | pmid=26942030 | doi=10.1155/2016/3750450 | pmc=4752974 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26942030 }} </ref> | *It commonly presents in the first two decades of life.<ref name="pmid26942030">{{cite journal| author=Stein JR, Reidman DA| title=Imaging Manifestations of a Subependymal Giant Cell Astrocytoma in Tuberous Sclerosis. | journal=Case Rep Radiol | year= 2016 | volume= 2016 | issue= | pages= 3750450 | pmid=26942030 | doi=10.1155/2016/3750450 | pmc=4752974 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26942030 }} </ref> | ||
* | *It becomes symptomatic, clinically and pathologically, between 8 to 19 years of age.<ref name="OuyangZhang2014">{{cite journal|last1=Ouyang|first1=Taohui|last2=Zhang|first2=Na|last3=Benjamin|first3=Thomas|last4=Wang|first4=Long|last5=Jiao|first5=Jiantong|last6=Zhao|first6=Yiqing|last7=Chen|first7=Jian|title=Subependymal giant cell astrocytoma: current concepts, management, and future directions|journal=Child's Nervous System|volume=30|issue=4|year=2014|pages=561–570|issn=0256-7040|doi=10.1007/s00381-014-2383-x}}</ref> | ||
===Race=== | ===Race=== | ||
Latest revision as of 19:49, 5 November 2019
|
Subependymal giant cell astrocytoma Microchapters |
|
Differentiating Subependymal Giant Cell Astrocytoma from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Subependymal giant cell astrocytoma epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Subependymal giant cell astrocytoma epidemiology and demographics |
|
FDA on Subependymal giant cell astrocytoma epidemiology and demographics |
|
CDC on Subependymal giant cell astrocytoma epidemiology and demographics |
|
Subependymal giant cell astrocytoma epidemiology and demographics in the news |
|
Blogs on Subependymal giant cell astrocytoma epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Ifeoma Odukwe, M.D. [2], Sujit Routray, M.D. [3]
Overview
Subependymal giant cell astrocytoma is the most common central nervous system tumor in patients with tuberous sclerosis complex. Approximately 10-20% of patients with tuberous sclerosis develop subependymal giant cell astrocytoma. It is a disease that tends to commonly affect the pediatric population with males being more affected than females.
Epidemiology and Demographics
Incidence
- The incidence of subependymal giant cell astrocytoma is approximately 0.027 per 100,000 person-years.[1]
Prevalence
- Subependymal giant cell astrocytoma is the most common central nervous system tumor in patients with tuberous sclerosis complex.[2]
- Approximately 10-20% of patients with tuberous sclerosis develop subependymal giant cell astrocytoma.[3]
Age
- Subependymal giant cell astrocytoma is a disease that tends to affect the pediatric, adolescent, and young adult population.[4]
- The mean age at diagnosis is 13 years.[5]
- It commonly presents in the first two decades of life.[6]
- It becomes symptomatic, clinically and pathologically, between 8 to 19 years of age.[2]
Race
- There is no racial predilection to subependymal giant cell astrocytoma.
Gender
References
- ↑ Nguyen HS, Doan NB, Gelsomino M, Shabani S, Awad AJ, Best B; et al. (2018). "Subependymal Giant Cell Astrocytoma: A Surveillance, Epidemiology, and End Results Program-Based Analysis from 2004 to 2013". World Neurosurg. 118: e263–e268. doi:10.1016/j.wneu.2018.06.169. PMID 29966782.
- ↑ 2.0 2.1 2.2 Ouyang, Taohui; Zhang, Na; Benjamin, Thomas; Wang, Long; Jiao, Jiantong; Zhao, Yiqing; Chen, Jian (2014). "Subependymal giant cell astrocytoma: current concepts, management, and future directions". Child's Nervous System. 30 (4): 561–570. doi:10.1007/s00381-014-2383-x. ISSN 0256-7040.
- ↑ Roth, Jonathan; Roach, E. Steve; Bartels, Ute; Jóźwiak, Sergiusz; Koenig, Mary Kay; Weiner, Howard L.; Franz, David N.; Wang, Henry Z. (2013). "Subependymal Giant Cell Astrocytoma: Diagnosis, Screening, and Treatment. Recommendations From the International Tuberous Sclerosis Complex Consensus Conference 2012". Pediatric Neurology. 49 (6): 439–444. doi:10.1016/j.pediatrneurol.2013.08.017. ISSN 0887-8994.
- ↑ 4.0 4.1 Campen CJ, Porter BE (2011). "Subependymal Giant Cell Astrocytoma (SEGA) Treatment Update". Curr Treat Options Neurol. 13 (4): 380–5. doi:10.1007/s11940-011-0123-z. PMC 3130084. PMID 21465222.
- ↑ Nabbout, R; Santos, M; Rolland, Y; Delalande, O; Dulac, O; Chiron, C (1999). "Early diagnosis of subependymal giant cell astrocytoma in children with tuberous sclerosis". Journal of Neurology, Neurosurgery & Psychiatry. 66 (3): 370–375. doi:10.1136/jnnp.66.3.370. ISSN 0022-3050.
- ↑ Stein JR, Reidman DA (2016). "Imaging Manifestations of a Subependymal Giant Cell Astrocytoma in Tuberous Sclerosis". Case Rep Radiol. 2016: 3750450. doi:10.1155/2016/3750450. PMC 4752974. PMID 26942030.
- ↑ Sun P, Kohrman M, Liu J, Guo A, Rogerio J, Krueger D (2012). "Outcomes of resecting subependymal giant cell astrocytoma (SEGA) among patients with SEGA-related tuberous sclerosis complex: a national claims database analysis". Curr Med Res Opin. 28 (4): 657–63. doi:10.1185/03007995.2012.658907. PMID 22375958.